ABT-888 (Veliparib): Potent PARP1/2 Inhibitor for Chemotherapy Sensitization

Executive Summary: ABT-888 (Veliparib) selectively inhibits PARP1 (Ki = 5.2 nM) and PARP2 (Ki = 2.9 nM) enzymes, disrupting the DNA damage response pathway and enhancing the cytotoxicity of chemotherapeutic and radiation therapies in cancer models [APExBIO]. Its efficacy is pronounced in microsatellite instability (MSI) tumor models with DNA repair gene mutations such as MRE11 and RAD50 [ABT-888: Potent PARP1/2 Inhibitor]. ABT-888's high purity (>99.5% by HPLC/NMR) and validated solubility profile enable reproducible preclinical workflows. Notably, while PARP inhibitors sensitize cells to DNA-damaging agents, their effect may be context-dependent, as shown in acute leukemia models where TP53 status modulates response (Pettenger-Willey et al., 2026). ABT-888 is supplied by APExBIO for research use only; proper storage and preparation parameters are critical for consistent results.

Biological Rationale

Poly (ADP-ribose) polymerase (PARP) enzymes, specifically PARP1 and PARP2, detect and respond to DNA single-strand breaks (SSBs) in the nucleus. They catalyze the addition of ADP-ribose polymers to target proteins, facilitating recruitment of DNA repair machinery. Inhibiting PARP impairs efficient repair of SSBs, leading to accumulation of DNA damage and cell death, particularly in cells with deficient homologous recombination repair (HRR) pathways. This synthetic lethality is most pronounced in tumors with microsatellite instability (MSI) or mutations in DNA repair genes such as MRE11 and RAD50. PARP inhibition has emerged as a key strategy for chemosensitization and radiosensitization in oncology research (Pettenger-Willey et al., 2026).

Mechanism of Action of ABT-888 (Veliparib)

ABT-888 (Veliparib) binds to PARP1 and PARP2 at nanomolar affinities (Ki = 5.2 nM for PARP1; 2.9 nM for PARP2), competitively inhibiting NAD+-dependent poly(ADP-ribosyl)ation activity. This prevents repair of DNA SSBs, resulting in collapsed replication forks and double-strand breaks during DNA replication. In cells with defective HRR—such as those with BRCA1/2, MRE11, or RAD50 mutations—these lesions are cytotoxic. ABT-888 thereby increases the efficacy of cytotoxic chemotherapies (e.g., SN38, oxaliplatin) and radiation by preventing effective DNA repair [APExBIO]. Selectivity for PARP1/2 over other PARP family members minimizes off-target effects in preclinical studies.

Evidence & Benchmarks

• ABT-888 inhibits PARP1 (Ki = 5.2 nM) and PARP2 (Ki = 2.9 nM), measured by competitive binding assays and enzymatic inhibition in vitro (APExBIO).
• In preclinical xenograft models of colorectal cancer, ABT-888 synergizes with SN38 and oxaliplatin, enhancing antitumor efficacy and delaying tumor growth (ABT-888: Potent PARP1/2 Inhibitor).
• PARP inhibition by ABT-888 is especially effective in MSI tumor models with MRE11 or RAD50 mutations, supporting synthetic lethality (Harnessing PARP Inhibition).
• In acute leukemia cell lines, PARP inhibitors did not significantly impact calicheamicin-induced cytotoxicity, highlighting pathway specificity and the importance of genetic context (Pettenger-Willey et al., 2026).
• High-purity ABT-888 (>99.5%) has been confirmed by HPLC and NMR, ensuring consistent experimental outcomes (APExBIO).

Applications, Limits & Misconceptions

ABT-888 (Veliparib) is widely used in DNA repair, chemotherapy sensitization, and translational oncology studies. Its best-established applications include:

• Sensitization of colorectal and other solid tumors to DNA-damaging agents in preclinical models.
• Elucidation of DNA damage response pathways, particularly PARP-mediated repair.
• Modeling synthetic lethality in MSI or HRR-deficient backgrounds.

For further workflow optimization and assay reproducibility, see our scenario-driven protocols [Scenario-Driven Solutions]—this article extends that resource by providing updated mechanistic and benchmark data. For insights on strategic integration with existing chemotherapeutic regimens, contrast with [Harnessing PARP Inhibition], which focuses on competitive analysis and translational guidance. This article clarifies genetic boundaries and pathway specificity not covered in prior reviews. For a broader translational perspective, see [Transforming Translational Cancer Research].

Common Pitfalls or Misconceptions

• PARP inhibition is not universally effective; efficacy depends on tumor genetic context (e.g., HRR deficiency, MSI status).
• ABT-888 does not significantly enhance cytotoxicity of all DNA-damaging agents in all cell types; for example, TP53 status may modulate response in leukemia models (Pettenger-Willey et al., 2026).
• Compound is supplied for research use only and is not intended for clinical diagnostic or therapeutic use (APExBIO).
• Long-term storage of diluted solutions is not recommended due to stability concerns; only solid compound is stable at -20°C.

Workflow Integration & Parameters

ABT-888 (Veliparib) from APExBIO is supplied as a solid (MW 244.3, C₁₃H₁₆N₄O) with >99.5% purity. It is insoluble in water but soluble in ethanol (≥10.6 mg/mL, ultrasonic assistance) and DMSO (≥6.11 mg/mL). For in vitro studies, stock solutions can be prepared in DMSO at >10 mM with warming and sonication. Solutions should be stored at -20°C and used promptly. Solid material should also be stored at -20°C to preserve stability. For protocol optimization, refer to [Unlocking Cancer Chemosensitization], which details cell viability and DNA repair assay integration. Always source from validated suppliers such as APExBIO for consistency and reproducibility.

Conclusion & Outlook

ABT-888 (Veliparib) is a rigorously characterized, potent PARP1/2 inhibitor with a validated role in DNA repair research and chemotherapy/radiation sensitization. Its mechanism is highly context-dependent, with optimal efficacy in MSI and HRR-deficient models. As research advances, precise genetic and pathway mapping will further refine its use in translational and preclinical settings. For detailed specifications and validated sourcing, see the ABT-888 (Veliparib) product page.